The Ministry of Health, Labor and Welfare (MHLW) on December 18 presented a proposal to define the scope of products…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY NIBIO to Strengthen Academia’s Drug Discovery Support Initiatives in Order to Evaluate 400 Research Themes by FY2015
October 4, 2013
-
ORGANIZATION JPMA Compliance Committee to Decide Penalties for Novartis for Diovan Case as Requested by Dr Teshirogi
October 3, 2013
-
BUSINESS Another Administrative Action Taken Against MTPC on Medway Injection; 3rd in 4 Years
October 2, 2013
-
REGULATORY Interim Report of Diovan Panel Fails to Lay Bare Who Altered Data, for What Purpose
October 1, 2013
-
BUSINESS Amgen Astellas BioPharma to Go on Stream Oct. 1; JV Chief Takahashi Eager to Make It a “Category Leader”
September 30, 2013
-
REGULATORY Japan Health Minister Meets Exec of Swiss Novartis, Seeks Cooperation in Diovan Probe
September 27, 2013
-
REGULATORY JPWA Seeks Generic Name Listing for Wider Range of Generics
September 27, 2013
-
BUSINESS 3 Pharma Groups Demand Permanent Introduction of Premium at CSIMC; Healthcare Rep Still Wary
September 26, 2013
-
BUSINESS Daiichi Sankyo Dogged by Renewed Quality Woes at Ranbaxy; FDA Mute on Details
September 26, 2013
-
ACADEMIA National University Hospital Council Urges Immediate Check-Up on Hospital’s Clinical Research Systems
September 25, 2013
-
BUSINESS Unique Marketing System Jacks Up Profits at Vital KSK; Customer-by-Customer Cost Analyses Lend Support
September 24, 2013
-
REGULATORY FTC’s Legal Intervention in Diovan Issue Possible, but Only with New Facts: Lawyer
September 20, 2013
-
BUSINESS MTPC Completes Acquisition of Medicago, Now Ready to Bolster Vaccine Development
September 20, 2013
-
BUSINESS Daiichi Sankyo, Mitsubishi UFJ Capital Establish New Fund to Support Ventures in Japan
September 19, 2013
-
BUSINESS Demand Growing for Transdermal Patches in Graying Japan, Drug Makers Gear Up for Development
September 18, 2013
-
REGULATORY MHLW Plans to Establish Ethics Committee Certification System to Improve the Quality of Clinical Research
September 18, 2013
-
BUSINESS Takeda Grants Arbor Exclusive Rights for Edarbi Family of Products in US
September 17, 2013
-
ORGANIZATION Transparency Guidelines: JPMA Says Requested Viewers’ Names, Affiliations Could Be Checked before Disclosing Individual Payment Information
September 13, 2013
-
BUSINESS Nippon Kayaku’s Filing of Remicade Biosimilar Heralds Age of Major Biologic Follow-Ons
September 12, 2013
-
REGULATORY PMDA Eyes Mandatory Electronic Filings for NDA Clinical Trial Data from FY2016
September 11, 2013
ページ
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
Will an “off-year” drug price revision happen in April 2025 or not? Over the last week, expectations have been up…
For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…